|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer. J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Ries L, Melbert D, Krapcho M, et al: SEER
cancer statistics review, 1975–2005. Bethesda, MD: National Cancer
Institute; pp. 1975–2005. 2008
|
|
3
|
McGuire WP III and Markman M: Primary
ovarian cancer chemotherapy: current standards of care. Br J
Cancer. 89:S3–S8. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Agarwal R and Kaye SB: Ovarian cancer:
strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crul M, Van Waardenburg R, Beijnen J and
Schellens J: DNA-based drug interactions of cis platin. Cancer
Treat Rev. 28:291–303. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cepeda V, Fuertes MA, Castilla J, Alonso
C, Quevedo C and Pérez JM: Biochemical mechanisms of cisplatin
cytotoxicity. Anticancer Agents Med Chem. 7:3–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar :
|
|
8
|
Sedletska Y, Giraud-Panis MJ and Malinge
JM: Cisplatin is a DNA-damaging antitumour compound triggering
multifactorial biochemical responses in cancer cells: importance of
apoptotic pathways. Curr Med Chem Anticancer Agents. 5:251–265.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mandic A, Hansson J, Linder S and Shoshan
MC: Cisplatin induces endoplasmic reticulum stress and
nucleus-independent apoptotic signaling. J Biol Chem.
278:9100–9106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stewart DJ: Mechanisms of resistance to
cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Galluzzi L, Senovilla L, Vitale I, et al:
Molecular mechanisms of cisplatin resistance. Oncogene.
31:1869–1883. 2012. View Article : Google Scholar
|
|
13
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang X, Fraser M, Moll UM, Basak A and
Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer:
modulation of p53 action on caspase-dependent mitochondrial death
pathway. Cancer Res. 66:3126–3136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li M, Balch C, Montgomery JS, et al:
Integrated analysis of DNA methylation and gene expression reveals
specific signaling pathways associated with platinum resistance in
ovarian cancer. BMC Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Team RC: R:A language and environment for
statistical computing. R foundation for Statistical Computing;
2005
|
|
17
|
Irizarry RA, Hobbs B, Collin F, et al:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smyth GK: Limma: Linear models for
microarray data. Bioinformatics and computational biology solutions
using R and Bioconductor Springer. pp. 397–420. 2005
|
|
19
|
Sherman BT, Huang da W, Tan Q, et al:
DAVID Knowledgebase: a gene-centered database integrating
heterogeneous gene annotation resources to facilitate
high-throughput gene functional analysis. BMC Bioinformatics.
8:4262007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Franceschini A, Szklarczyk D, Frankild S,
et al: STRING v9.1: protein-protein interaction networks, with
increased coverage and integration. Nucleic Acids Res.
41:D808–D815. 2013. View Article : Google Scholar :
|
|
21
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar :
|
|
22
|
Nepusz T, Yu H and Paccanaro A: Detecting
overlapping protein complexes in protein-protein interaction
networks. Nat Methods. 9:471–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rizzo S, Hersey JM, Mellor P, et al:
Ovarian cancer stem cell-like side populations are enriched
following chemotherapy and overexpress EZH2. Mol Cancer Ther.
10:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu S, Yu L, Li Z, et al: Overexpression of
EZH2 contributes to acquired cisplatin resistance in ovarian cancer
cells in vitro and in vivo. Cancer Biol Ther. 10:788–795. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bragado P, Armesilla A, Silva A and Porras
A: Apoptosis by cisplatin requires p53 mediated p38α MAPK
activation through ROS generation. Apoptosis. 12:1733–1742. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qin LF and Ng IO: Induction of apoptosis
by cisplatin and its effect on cell cycle-related proteins and cell
cycle changes in hepatoma cells. Cancer Lett. 175:27–38. 2002.
View Article : Google Scholar
|
|
27
|
Tsang DP and Cheng AS: Epigenetic
regulation of signaling pathways in cancer: Role of the histone
methyltransferase EZH2. J Gastroenterol Hepatol. 26:19–27. 2011.
View Article : Google Scholar
|
|
28
|
Hu S, Yu L, Li Z, et al: Overexpression of
EZH2 contributes to acquired cisplatin resistance in ovarian cancer
cells in vitro and in vivo. Cancer Biol Ther. 10:788–795. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rizzo S, Hersey JM, Mellor P, et al:
Ovarian cancer stem cell-like side populations are enriched
following chemotherapy and overexpress EZH2. Mol Cancer Ther.
10:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lv Y, Yuan C, Xiao X, et al: The
expression and significance of the enhancer of zeste homolog 2 in
lung adenocarcinoma. Oncol Rep. 28:147–154. 2012.PubMed/NCBI
|
|
31
|
Caldon CE, Sergio CM, Kang J, et al:
Cyclin E2 overexpression is associated with endocrine resistance
but not insensitivity to CDK2 inhibition in human breast cancer
cells. Mol Cancer Ther. 11:1488–1499. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng L, Zhao Y, Feng H and Liu Y:
Endocrine resistance in breast cancer. Climacteric. 1–7. 2013.
|
|
33
|
Tu SH, Ho CT, Liu MF, et al: Luteolin
sensitises drug-resistant human breast cancer cells to tamoxifen
via the inhibition of cyclin E2 expression. Food Chem.
141:1553–1561. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+Breast cancer and tamoxifen
resistance. Plos One. 9:e917712014. View Article : Google Scholar
|
|
35
|
Gao K, Lockwood WW, Li J, Lam W and Li G:
Genomic analyses identify gene candidates for acquired irinotecan
resistance in melanoma cells. Int J Oncol. 32:1343–1349.
2008.PubMed/NCBI
|
|
36
|
Klebig C, Korinth D and Meraldi P: Bub1
regulates chromosome segregation in a kinetochore-independent
manner. J Cell Biol. 185:841–858. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jeganathan K, Malureanu L, Baker DJ,
Abraham SC and van Deursen JM: Bub1 mediates cell death in response
to chromosome missegregation and acts to suppress spontaneous
tumorigenesis. J Cell Biol. 179:255–267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pinto M, Vieira J, Ribeiro FR, et al:
Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is
associated with genomic complexity in clear cell kidney carcinomas.
Cell Oncol. 30:389–395. 2008.PubMed/NCBI
|
